Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome

This study has been completed.
Sponsor:
Information provided by:
UCB Pharma
ClinicalTrials.gov Identifier:
NCT00135993
First received: August 24, 2005
Last updated: September 24, 2014
Last verified: September 2009